Philip Friedlander

8.2k total citations · 2 hit papers
61 papers, 3.8k citations indexed

About

Philip Friedlander is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Philip Friedlander has authored 61 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 35 papers in Molecular Biology and 20 papers in Immunology. Recurrent topics in Philip Friedlander's work include Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (19 papers) and CAR-T cell therapy research (18 papers). Philip Friedlander is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (19 papers) and CAR-T cell therapy research (18 papers). Philip Friedlander collaborates with scholars based in United States, Germany and France. Philip Friedlander's co-authors include Carol Prives, Axel Hauschild, Charles M. Rudin, Luc Dirix, Anne Lynn S. Chang, Sarah T. Arron, James Solomon, Aleksandar Sekulić, Simon Yoo and John D. Hainsworth and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Philip Friedlander

58 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Jason Chesney, Igor Puzanov et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Friedlander United States	22	2.2k	2.1k	735	728	605	61	3.8k
Lyn M. Duncan United States	22	1.7k 0.7×	1.8k 0.9×	323 0.4×	685 0.9×	312 0.5×	41	3.3k
Barry M. Kacinski United States	40	1.6k 0.7×	1.3k 0.6×	558 0.8×	1.2k 1.7×	618 1.0×	94	4.1k
Toshiro Kageshita Japan	28	2.9k 1.3×	2.8k 1.3×	369 0.5×	1.7k 2.3×	431 0.7×	135	5.1k
Eddy C. Hsueh United States	41	1.6k 0.7×	3.0k 1.4×	502 0.7×	2.5k 3.4×	226 0.4×	95	5.1k
Ragini R. Kudchadkar United States	33	1.6k 0.7×	2.6k 1.2×	529 0.7×	1.3k 1.7×	294 0.5×	128	3.9k
Aleksandar Sekulić United States	23	2.7k 1.2×	982 0.5×	1.3k 1.7×	245 0.3×	1.2k 1.9×	55	3.7k
Adam I. Riker United States	35	2.2k 1.0×	1.6k 0.8×	312 0.4×	1.4k 1.9×	145 0.2×	100	4.4k
Adriano Piris United States	27	1.8k 0.8×	2.0k 1.0×	307 0.4×	606 0.8×	274 0.5×	69	3.5k
Michal Lotem Israel	29	1.9k 0.8×	3.4k 1.6×	286 0.4×	1.8k 2.4×	178 0.3×	106	4.9k
Lee D. Cranmer United States	30	1.1k 0.5×	1.9k 0.9×	457 0.6×	822 1.1×	105 0.2×	127	3.3k

Countries citing papers authored by Philip Friedlander

Since Specialization

Citations

This map shows the geographic impact of Philip Friedlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Friedlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Friedlander more than expected).

Fields of papers citing papers by Philip Friedlander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Friedlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Friedlander. The network helps show where Philip Friedlander may publish in the future.

Co-authorship network of co-authors of Philip Friedlander

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Friedlander. A scholar is included among the top collaborators of Philip Friedlander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Friedlander. Philip Friedlander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kudelka, Matthew R., Allison L. Richards, Philip Friedlander, et al.. (2024). Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma. Journal for ImmunoTherapy of Cancer. 12(11). e009609–e009609.

2.

Chesney, Jason, Igor Puzanov, Frances A. Collichio, et al.. (2023). Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. Journal for ImmunoTherapy of Cancer. 11(5). e006270–e006270. 60 indexed citations

3.

Leiter, Amanda, Emily Carroll, Robert Yanagisawa, et al.. (2020). SAT-411 Vitamin D Levels and Risk of Thyroid Immune Related Adverse Events in Patients on Immune Checkpoint Inhibitors. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

4.

Kyi, Chrisann, Vladimir Roudko, Rachel Lubong Sabado, et al.. (2018). Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. Clinical Cancer Research. 24(20). 4937–4948. 97 indexed citations

5.

Friedlander, Philip, et al.. (2018). A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. Journal for ImmunoTherapy of Cancer. 6(1). 90–90. 36 indexed citations

6.

Friedlander, Philip, David E. Fisher, Chrisann Kyi, et al.. (2017). Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. Journal for ImmunoTherapy of Cancer. 5(1). 67–67. 34 indexed citations

7.

Chesney, Jason, Igor Puzanov, Frances A. Collichio, et al.. (2017). Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology. 36(17). 1658–1667. 471 indexed citations breakdown →

8.

Kyi, Chrisann, Rachel Lubong Sabado, Yvonne M. Saenger, et al.. (2016). In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. Journal of Clinical Oncology. 34(15_suppl). 3086–3086. 4 indexed citations

9.

Sekulić, Aleksandar, Michael R. Migden, Karl D. Lewis, et al.. (2015). Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology. 72(6). 1021–1026.e8. 154 indexed citations

10.

Middleton, Mark R., Philip Friedlander, Omid Hamid, et al.. (2015). Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology. 26(10). 2173–2179. 69 indexed citations

11.

Holcombe, Randall F., et al.. (2015). Impact of inpatient radiation on length of stay and health care costs. The Journal of Community and Supportive Oncology. 13(11). 399–404. 6 indexed citations

12.

Saenger, Yvonne M., Jay Magidson, Yichun Fu, et al.. (2014). Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clinical Cancer Research. 20(12). 3310–3318. 31 indexed citations

13.

Kaufman, Howard L., Michael Pan, Sebastian Bernardo, et al.. (2013). Oncolytic virus therapy for cancer. PubMed. 2. 31–31. 52 indexed citations

14.

Bernardo, Sebastian, Марина Москаленко, Michael Pan, et al.. (2012). Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Research. 23(1). 47–54. 43 indexed citations

15.

Sekulić, Aleksandar, Michael R. Migden, Anthony E. Oro, et al.. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 366(23). 2171–2179. 1011 indexed citations breakdown →

16.

Grbovic, Olivera M., Andrea Basso, Ayana Sawai, et al.. (2005). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of Sciences. 103(1). 57–62. 228 indexed citations

17.

Baptiste, Nicole, Philip Friedlander, Xinbin Chen, & Carol Prives. (2002). The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 21(1). 9–21. 114 indexed citations

18.

Baptiste, Nicole, Philip Friedlander, Xinbin Chen, & Carol Prives. (2002). The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 21(1). 9–21. 6 indexed citations

19.

Friedlander, Philip, Yann Legros, Thierry Soussi, & Carol Prives. (1996). Regulation of Mutant p53 Temperature-sensitive DNA Binding. Journal of Biological Chemistry. 271(41). 25468–25478. 90 indexed citations

20.

Prives, Carol, Jill Bargonetti, George E. Farmer, et al.. (1994). DNA-binding Properties of the p53 Tumor Suppressor Protein. Cold Spring Harbor Symposia on Quantitative Biology. 59(0). 207–213. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact